Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E65.83 EPS (ttm)0.96 Insider Own0.11% Shs Outstand1.26B Perf Week0.46%
Market Cap78.22B Forward P/E9.42 EPS next Y6.73 Insider Trans-0.01% Shs Float1.25B Perf Month6.56%
Income1.27B PEG38.84 EPS next Q1.91 Inst Own80.10% Short Float1.72% Perf Quarter0.59%
Sales23.15B P/S3.38 EPS this Y1.10% Inst Trans0.07% Short Ratio2.19 Perf Half Y-18.29%
Book/sh13.90 P/B4.56 EPS next Y-0.84% ROA2.10% Target Price72.46 Perf Year0.21%
Cash/sh19.41 P/C3.26 EPS next 5Y1.70% ROE6.30% 52W Range56.56 - 85.97 Perf YTD8.70%
Dividend2.72 P/FCF16.41 EPS past 5Y-10.50% ROI9.50% 52W High-22.04% Beta0.45
Dividend %4.29% Quick Ratio3.10 Sales past 5Y-2.00% Gross Margin79.00% 52W Low18.49% ATR1.23
Employees11800 Current Ratio3.30 Sales Q/Q17.40% Oper. Margin10.90% RSI (14)76.34 Volatility2.29% 2.03%
OptionableYes Debt/Eq1.68 EPS Q/Q131.00% Profit Margin5.50% Rel Volume2.23 Prev Close63.33
ShortableYes LT Debt/Eq1.59 EarningsOct 28 AMC Payout271.60% Avg Volume9.86M Price67.02
Recom2.50 SMA2012.05% SMA5011.47% SMA200-1.98% Volume11,646,304 Change5.83%
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $83
Jan-04-21Upgrade Guggenheim Neutral → Buy
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
Oct-28-20Initiated UBS Neutral $61
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Jan-19-21 12:39PM  
09:31AM  
08:00AM  
Jan-18-21 07:00AM  
Jan-16-21 11:17PM  
Jan-15-21 05:45PM  
04:37PM  
Jan-14-21 02:36PM  
Jan-13-21 02:11PM  
05:51AM  
Jan-12-21 04:31PM  
03:26PM  
03:18PM  
08:00AM  
Jan-11-21 03:39PM  
11:20AM  
10:32AM  
10:21AM  
09:22AM  
08:25AM  
06:24AM  
06:00AM  
Jan-08-21 09:11AM  
Jan-07-21 05:45PM  
Jan-06-21 10:26AM  
08:00AM  
Jan-05-21 09:00AM  
Jan-04-21 11:53AM  
10:00AM  
Jan-03-21 03:58AM  
Jan-01-21 07:15AM  
Dec-31-20 02:41PM  
07:02AM  
Dec-30-20 09:28AM  
Dec-29-20 10:53AM  
Dec-28-20 04:01PM  
07:00AM  
Dec-26-20 02:16AM  
Dec-23-20 07:03AM  
Dec-22-20 12:56PM  
Dec-21-20 05:45PM  
04:01PM  
Dec-18-20 12:21PM  
09:12AM  
06:30AM  
Dec-17-20 04:21PM  
10:14AM  
09:24AM  
Dec-16-20 04:33PM  
01:42PM  
01:37PM  
08:00AM  
05:17AM  
03:01AM  
Dec-15-20 05:45PM  
04:37PM  
04:15PM  
09:54AM  
Dec-14-20 09:14AM  
08:31AM  
Dec-13-20 06:35AM  
Dec-11-20 09:21PM  
01:03PM  
Dec-10-20 04:48PM  
10:23AM  
10:14AM  
10:02AM  
09:20AM  
08:17AM  
08:00AM  
06:56AM  
Dec-09-20 05:45PM  
11:00AM  
Dec-08-20 11:45PM  
04:05PM  
01:09PM  
09:55AM  
Dec-07-20 04:20PM  
01:27PM  
12:32PM  
06:35AM  
Dec-06-20 03:00PM  
12:30PM  
Dec-05-20 12:30PM  
10:00AM  
10:00AM  
03:38AM  
Dec-04-20 04:21PM  
Dec-03-20 06:47AM  
Dec-02-20 05:27PM  
Dec-01-20 09:00AM  
08:39AM  
07:00AM  
Nov-30-20 08:54AM  
07:30AM  
Nov-29-20 09:40PM  
07:31AM  
Nov-28-20 07:11AM  
06:45AM  
Nov-27-20 06:30AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM